Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison

Published:2024-04-20 Issue:6 Volume:41 Page:2486-2499
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

van Steen Cécile^ORCID,Celico Lorenzo,Spaepen Erik,Hagenacker Tim^ORCID,Meuth Sven G.^ORCID,Ruck Tobias^ORCID,Smith A. Gordon^ORCID,Bodicoat Danielle H.^ORCID,de Francesco Maria^ORCID,Iannazzo Sergio^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-024-02856-3.pdf

Reference13 articles.

1. Howard JF, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526–36.

2. Szczudlik P, et al. Determinants of quality of life in myasthenia gravis patients. Front Neurol. 2020;11: 553626.

3. Yang Y, et al. Quality of life in 188 patients with myasthenia gravis in China. Int J Neurosci. 2016;126(5):455–62.

4. Narayanaswami P, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114–22.

5. Wolfe GI, et al. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487–9.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP